Investors

Investors2018-11-29T05:18:43+00:00

BioVie Non-confidential Company Slide Deck

Please download our non-confidential investor presentation for more specific information about how we intend to address the unmet medical need of acites due to liver cirrhosis.

Recent Press

1005, 2017

Hari Kuma Joins BioVie Board

Distinguished BioPharma Executive Hari Kumar Joins BioVie Board of Directors and Purchases Company Stock May 10, 2017 BEVERLY, MA–(Marketwired – May 10, 2017) – BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today welcomed Dr. Hari Kumar, a highly accomplished biopharmaceutical industry executive, to its Board of Directors as an independent director. In addition, [...]

2504, 2017

BioVie Signs Cooperative Research and Development Agreement (CRADA) to Conduct a Phase 2a Clinical Trial

BioVie Signs Cooperative Research and Development Agreement (CRADA) to Conduct a Phase 2a Clinical Trial of BIV201 in Refractory Ascites Patients April 25, 2017 BEVERLY, MA–(Marketwired – April 25, 2017) – BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today announced the signing of a Cooperative Research and Development Agreement (CRADA) to conduct a [...]

304, 2017

BioVie Receives FDA Clearance for Phase 2a Clinical Trial and Attains Patent Allowance, Satisfies Conditions to Commence Funding Under the $12m Aspire Agreement

BioVie Receives FDA Clearance for Phase 2a Clinical Trial and Attains Patent Allowance, Satisfies Conditions to Commence Funding Under the $12m Aspire Agreement April 3, 2017 BEVERLY, MA–(Marketwired – April 03, 2017) – BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, is pleased to announce that it has received notice from the US Food [...]

1503, 2017

Julie G. Anderson Joins BioVie as Independent Director

Julie G. Anderson Joins BioVie as Independent Director and Investor March 15, 2017 BEVERLY, MA–(Marketwired – March 15, 2017) – BioVie Inc. (OTCQB: BIVI), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, is pleased to announce the appointment of Julie G. Anderson as an independent member of the Company’s Board of Directors. Ms. Anderson brings an impressive experience [...]

603, 2017

BioVie Announces Uplisting to OTCQB Market

BioVie Announces Uplisting to OTCQB Market  March 6, 2017 BEVERLY, MA–(Marketwired – March 06, 2017) – BioVie Inc. (OTCQB: BIVI), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, announced today that its stock has commenced trading on the OTCQB market after successfully uplisting from the OTC Pink market.OTCQB membership provides enhanced investor benefits including higher reporting standards, increased [...]

2202, 2017

BioVie Submits Additional Information to FDA for BIV201 Clinical Trial in Ascites Patients

BioVie Submits Additional Information to FDA for BIV201 Clinical Trial in Ascites Patients February 22, 2017 BEVERLY, MA–(Marketwired – February 22, 2017) – BioVie Inc. (OTC PINK: BIVI), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, announced today that it has submitted a complete response to the U.S. Food and Drug Administration (FDA) addressing the issues identified in [...]

501, 2017

BioVie Enters Into A $12 Million Common Stock Purchase Agreement With Aspire Capital Fund

BIV201 Clinical Trial May Begin This Spring January 5, 2017 BEVERLY, MA–(Marketwired – January 05, 2017) – BioVie Inc. (OTC PINK: BIVI), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, is pleased to announce the completion of a Common Stock Purchase Agreement with Aspire Capital Fund, LLC, a Chicago-based institutional investor, to purchase up to $12 million of BioVie [...]

712, 2016

Accomplished Healthcare Executive Jim Lang Invests and Joins BioVie’s Board of Directors

Accomplished Healthcare Executive Jim Lang Invests and Joins BioVie’s Board of Directors – December 07, 2016 December 7, 2016 BEVERLY, MA–(Marketwired – December 07, 2016) – BioVie Inc. (OTC PINK: BIVI), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, is pleased to announce the appointment of Mr. James Lang as an independent member of the Company’s Board of [...]

2911, 2016

BioVie Submits Investigational New Drug Application for BIV201 for Treating Refractory Ascites due to Liver Cirrhosis

Anticipates Initiation of US Clinical Trial in 2017 November 29, 2016 BEVERLY, MA–(Marketwired – November 29, 2016) – BioVie Inc. (OTC PINK: BIVI), a development-stage company focused on the discovery, development and commercialization of innovative drug therapies in liver disease, today announced the submission of an Investigational New Drug (IND) application for new drug candidate BIV201 to the US Food and Drug Administration (FDA). BIV201 has the [...]

2209, 2016

BioVie Updates on Link Between NASH, Liver Cirrhosis, and Ascites

BioVie Updates on Link Between NASH, Liver Cirrhosis, and Ascites September 22, 2016 BEVERLY, MA–(Marketwired – September 22, 2016) – BioVie Inc. (OTC PINK: BIVI) (the “Company”), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies, announced that its scientific team has completed an assessment of the link between nonalcoholic steatohepatitis (NASH), chronic liver cirrhosis, and ascites. The Company’s new drug therapy [...]

Forward Looking Statements

This website contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause BioVie’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. BioVie has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are BioVie’s need for, and the availability of, substantial capital in the future to fund its operations and research and development. The fact is that BioVie’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in BioVie’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. BioVie undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

This website uses cookies and third party services. Settings Ok

Cookies

This site uses cookies and third party services

Third party embeds

This site allows third-party services to track activity on this site